Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Receivables: 2016-2024

Historic Receivables for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $36.4 million.

  • Akebia Therapeutics' Receivables rose 103.80% to $69.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.9 million, marking a year-over-year increase of 79.56%. This contributed to the annual value of $36.4 million for FY2024, which is 14.65% down from last year.
  • Per Akebia Therapeutics' latest filing, its Receivables stood at $36.4 million for FY2024, which was down 14.65% from $42.6 million recorded in FY2023.
  • Over the past 5 years, Akebia Therapeutics' Receivables peaked at $70.7 million during FY2021, and registered a low of $3.7 million during FY2020.
  • In the last 3 years, Akebia Therapeutics' Receivables had a median value of $42.2 million in 2022 and averaged $40.4 million.
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 93.15% in 2020, then skyrocketed by 1,787.18% in 2021.
  • MRY analysis of 5 years shows Akebia Therapeutics' Receivables stood at $3.7 million in 2020, then surged by 1,787.18% to $70.7 million in 2021, then plummeted by 40.31% to $42.2 million in 2022, then rose by 1.04% to $42.6 million in 2023, then fell by 14.65% to $36.4 million in 2024.
  • Its last three reported values are $36.4 million in FY2024, $42.6 million for FY2023, and $42.2 million during FY2022.